Institute for International Research

IBC's China 2009 Pharmaceutical R&D Summit, set in Shanghai, China in April 2009, will once again bring together the industry's luminaries to discuss the global role of China's pharmaceutical industry, its transition from imitation to innovation, as well as share case studies of best practices, successful business models and scientific advances from discovery and early development to clinical trials.

We invite you to be a witness to the life-changing moments in China's pharmaceutical history. Join us today and capitalize on China's growing pharmaceutical market to become the partner-of-choice for your collaborators.

Join us today and position yourself as the Partner-of-Choice in China - the New Frontier in Global Pharmaceutical R&D.

Why in China?

At IBC's China 2008 Pharmaceutical R&D Summit held in March this year, we marked the arrival and maturity of China as a major force in the global pharmaceutical R&D industry. With more than 350 attendees from China, US, Europe, Singapore, Korea, India, Japan and rest of world, the event was a showcase of who's who in the world pharmaceutical stage. Representatives from all the major pharmaceutical companies came to participate in the annual event, and share their insights on their strategies for international cooperation with China.

Moving into 2009, big pharmaceutical companies are increasingly relying on China for integrated research and development. Outsourcing of drug R&D is becoming more strategically important to these multinationals, especially as key blockbusters including Fosamax and Lipitor, will soon go off patent and be exposed to competition from low-cost generics. With a dire shortage of promising new drugs in the pipeline, skyrocketing development costs in the West, and migration of global talent, these big pharmaceutical companies are looking toward China's multi-billion dollar pharmaceutical industry as their next growth frontier.

To the Chinese biotechs and CROs, this is a unique opportunity to not only establish a foothold in the burgeoning pharmaceutical industry at home, but also to find partners for the various business models, from service provision to risk-share collaborations, to joint ventures or M&As.

» Who You Will Meet
» Companies Represented in 2008

Did you know?

• China's pharmaceutical market's growth rate for the past 20 years has averaged at 18 - 20%, significantly higher than US and European growth during the same time period (7 - 9%).
• The pharmaceutical market in China (excluding Hong Kong) is estimated at US$22.6 billion (including TCM of $5-6 billion) in 2007. This makes China one of the largest markets in the world, and second only to Japan in Asia.
• By 2020, investments in R&D are expected to be 2.5% of the country's GDP.
• Outsourced R&D activities to India and China make up 20% to 30% of total global clinical trials.
• There's a growing prevalence of Chinese and Indian inventors in global pharma patent applications. In 2006, 8.5% of all pharma patent applications filed through the World IP Organization included an inventor located in China, and 5.5% ncluded one in India.
• The State Council of the People's Republic of China announced in their 11th Five-Year plans that they will be devoting significant amount of resources into developing frontier technologies, particularly in the sectors of biology and advanced manufacturing technologies.
• WuXi PharmaTech is China's first CRO to list on the NYSE, raising $184.6 million in an IPO in August 2007.